Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Apr 29:2025:1976122.
doi: 10.1155/cric/1976122. eCollection 2025.

Heartbreak From Gilteritinib: Two Case Reports of Delayed Onset Cardiotoxicity

Kristi Dutta  1 , Ethan D Kotloff  1 , Manu M Mysore  2
Affiliations
Case Reports

Heartbreak From Gilteritinib: Two Case Reports of Delayed Onset Cardiotoxicity

Kristi Dutta et al. Case Rep Cardiol. .

Abstract

Activating mutations of FMS-like Tyrosine Kinase 3 (FLT3) occur in a subset of patients with acute myeloid leukemia (AML) and confer a poor prognosis. Gilteritinib, an oral FLT3 inhibitor approved for the treatment of relapsed or refractory AML, has been shown to improve survival and remission rates compared with salvage chemotherapy. This case report presents two patients initiated on gilteritinib for relapsed AML who developed new onset left ventricular systolic dysfunction. After ruling out other common etiologies, gilteritinib was discontinued due to concern for cancer therapy-related cardiac dysfunction with subsequent improvement in ejection fraction. These cases demonstrate a rare but serious adverse effect of gilteritinib, cardiotoxicity manifested as left ventricular systolic dysfunction, for which more studies are needed to elucidate the underlying pathophysiology.

Keywords: cardio-oncology; gilteritinib; heart failure.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Global longitudinal strain (GLS) measurements pre- and postinitiation of gilteritinib in Case 1.
See this image and copyright information in PMC

References

    1. Perl A. E., Martinelli G., Cortes J. E., et al. Gilteritinib or Chemotherapy for Relapsed or RefractoryFLT3-Mutated AML. New England Journal of Medicine . 2022;386(19):p. 1868. doi: 10.1056/NEJMx220003. Erratum for: N Engl J Med. 2019 Oct 31;381(18):1728-1740. PMID: 35544407. - DOI - PubMed
    1. Gronich N., Lavi I., Barnett-Griness O., Saliba W., Abernethy D. R., Rennert G. Tyrosine Kinase-Targeting Drugs-Associated Heart Failure. British Journal of Cancer . 2017;116(10):1366–1373. doi: 10.1038/bjc.2017.88. - DOI - PMC - PubMed
    1. Naranjo C. A., Busto U., Sellers E. M., et al. A Method for Estimating the Probability of Adverse Drug Reactions. Clinical Pharmacology and Therapeutics . 1981;30(2):239–245. doi: 10.1038/clpt.1981.154. - DOI - PubMed
    1. Kim L., Fowler B., Campbell C. M., et al. Acute Cardiotoxicity After Initiation of the Novel Tyrosine Kinase Inhibitor Gilteritinib for Acute Myeloid Leukemia. Cardiooncology . 2021;7(1):p. 36. doi: 10.1186/s40959-021-00122-x. - DOI - PMC - PubMed
    1. Astellas Pharma. XOSPATA (Gilteritinib): US Prescribing Information. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.Pdf .

Publication types

LinkOut - more resources